News & media

The latest news about Watrium
05 February 2021

Watrium continues its support of London AIM-listed Distribution Finance Capital Holdings Plc (“DF Capital”) through participation in a GBP 40 million private placement.  DF Capital was recently awarded their banking licence. The net proceeds of the private placement will be utilised to accelerate the Group's business plan and loan book growth by unlocking significant and current pipeline of demand. The additional equity will remove the current GBP 270 million constraint...

29 September 2020
DF Capital granted banking licence

Distribution Finance Capital Holdings plc, a niche lender providing working capital solutions to dealers and manufacturers across the UK, today announces that, following the resubmission of its banking licence application in August 2019, the Company has received confirmation from the Prudential Regulation Authority (PRA) that the PRA, with the consent of the Financial Conduct Authority (FCA), has authorised its...

23 September 2020
Watrium temporarily on the move

While Watrium refurbish its headquarters at Kanalen 5,  Tjuvholmen in Oslo, Norway, the company will temporarily move to its Oslo Atrium office building at Dronning Eufemias gate 6A in Bjørvika in Oslo, from 21 September 2020 to April 2021. Throughout this period, phone number remains the same and business partners should use the following addresses:  ...

Watrium logo
29 June 2020

2019 was an eventful year for Watrium, with several exciting new investments, overall strong development for the portfolio companies, attractive and well positioned real estate assets, and moving into 2020 from a position of strength with a robust balance sheet. The continued value creation from a balanced and diversified investment portfolio, is the result of an investment strategy that Watrium has diligently followed for a long time. Notable business milestones in 2019 includes the investments in HitecVision and CMR Surgical, the listings of Ultimovacs and DF Capital, and the...

28 May 2020
Watrium continues backing of Ultimovacs

Watrium continues its support of Oslo-listed Ultimovacs ASA through participation in a NOK 160 million private placement in the pharmaceutical company. Ultimovacs is developing novel immunotherapies against cancer. The net proceeds of the private placement will secure Ultimovacs' funding of its part of the expected project costs in the new randomized phase II trial to...

27 September 2019
Watrium supports CMR Surgical in transforming surgery

CMR Surgical Limited, the Company developing, manufacturing and marketing the next-generation surgical robotic system, Versius®, has raised £195 million ($240 million) to fully fund the global commercialisation of the business.

03 June 2019
Watrium underwrites listing of Ultimovacs

Ultimovacs is a pharmaceutical company developing novel immunotherapies against cancer. The lead product candidate is UV1, a peptide-based vaccine inducing a specific T cell response against the universal cancer antigen telomerase.

09 May 2019
Watrium supports listing of DF Capital

Watrium supports the listing of DF Capital on AIM as cornerstone investor.

17 April 2019
Watrium partners with HitecVision

Watrium partners with HitecVision by acquiring the interests of the Gjedebo family in HitecVision AS.